NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Alpha Teknova, Inc. TKNO
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$40.5M
▲ 7.4% vs FY2024
EPS · FY25
$-0.32
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-22.8%
Net margin · FY25
-42.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 40.5M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 43 cents on every revenue dollar this year.
Per share
USD -0.32
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-22.8%
Return on equity, FY2025
ROE
Operating margin-41.9%
Net margin-42.6%
Return on assets-15.5%
Each USD of equity lost 23 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+5.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−0.7%
+5.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 103.6M
total assets, end of FY2025
Total assetsUSD 103.6M
EquityUSD 68.8M
CashUSD 5.9M
Gross debtUSD 13.1M
Net debtUSD 7.2M
Current ratio4.58×
Net debt stands at 10% of equity.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
Income tax $B
0.0
−0.0
−0.0
−0.0
−0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
EPS, diluted $
−0.32
−0.57
−1.16
−1.69
−0.61
0.16
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−22.8
−31.0
−38.7
−39.1
−12.3
21.3
Shares out B
0.05
0.05
0.04
0.03
0.03
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
24 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed